BridgeBio Pharma Inc [BBIO] stock prices are up 1.13% to $25.08 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BBIO shares have gain 2.33% over the last week, with a monthly amount drifted -12.73%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on September 04, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $46. On January 31, 2024, BMO Capital Markets initiated with a Market Perform rating and assigned a price target of $37 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $58 on December 08, 2023. Wells Fargo initiated its recommendation with a Overweight. Citigroup started tracking with a Buy rating for this stock on November 07, 2023, and assigned it a price target of $42. In a note dated October 24, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $50 on this stock.
The stock price of BridgeBio Pharma Inc [BBIO] has been fluctuating between $21.62 and $44.32 over the past year. Currently, Wall Street analysts expect the stock to reach $44.9 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $25.08 at the most recent close of the market. An investor can expect a potential return of 79.03% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
The BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 219.12M for trailing twelve months, representing a surge of 32.11%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.3%, Pretax Profit Margin comes in at -2.09%, and Net Profit Margin reading is -2.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is 0.39 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.47 points at the first support level, and at 23.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.52, and for the 2nd resistance point, it is at 25.95.
Ratios To Look Out For
It’s worth pointing out that BridgeBio Pharma Inc [NASDAQ:BBIO]’s Current Ratio is 4.59. In addition, the Quick Ratio stands at 4.59 and the Cash Ratio stands at 4.07. Considering the valuation of this stock, the price to sales ratio is 21.52.
Transactions by insiders
Recent insider trading involved KKR Genetic Disorder L.P., 10% Owner, that happened on Sep 13 ’24 when 5.8 million shares were sold. Affiliate, KKR Genetic Disorder L.P. completed a deal on Sep 13 ’24 to buy 5.8 million shares. Meanwhile, Chief Executive Officer Kumar Neil sold 27389.0 shares on Aug 19 ’24.
